New approaches to the treatment of endometrial pathology in patients with extragenital diseases

With purpose to increase efficiency and decrease frequencies of complications after treatment of endo- and myometrium pathology in patients of the perimenopausal period with extragenital pathology this study has been conducted. Different conducted clinic-laboratory, instrumental and pathology examination were performed. 130 patients of the perimenopausal period from somatic pathology (46-60 years) were divided into representative groups. The main group consisted of 100 patients who suffered from endometrium hyperplasia and adenomyosis. The control group included 30 healthy women without pathology of endoand myometrium. Patients of the main group, depending on the applied treatment-and-prophylactic approach, were divided into two subgroups. Group I included 50 women who underwent hysteroscopy and intrauterine cryosurgery, magnesium supplements, and thromboembolic complications (TEC) prevention measures. Patients of the II group (50 patients) underwent hysteroscopy and treatment and prevention measures following the recommendations of the Protocol of the Ministry of Health of Ukraine (№ 676 of 31.12.2004). T he effectiveness of the proposed approach to diagnosis, minimally invasive treatment (hysteroscopy and intrauterine cryosurgery), and prevention of TEC and inflammatory complications of endo pathology- and myometrium in patients of the perimenopausal period with extragenital pathology, according to the clinic-laboratory and cytomorphological examination, the results of ultrasound was 82.0 %, prevention of TEC and inflammatory complications — 100 % cases. According to generally accepted approaches, the effectiveness of treatment was 36.0 %, TEC prevention — 96.0 %, prevention of inflammatory complications — 78.0 %.

Download Full-text

Clinical Application of Minimally Invasive Surgery in Pain and Complications after Spinal Trauma

Journal of Clinical and Nursing Research ◽

10.26689/jcnr.v5i1.1774 ◽

2021 ◽

Vol 5 (1) ◽

Author(s):

Tianhui Liu ◽

Xiaoying Gao ◽

Jianmin Cui

Keyword(s):

Minimally Invasive Surgery ◽

Minimally Invasive ◽

Invasive Surgery ◽

Postoperative Recovery ◽

Spinal Trauma ◽

Minimally Invasive Treatment ◽

Control Group ◽

Study Group ◽

Invasive Treatment ◽

Treatment Scheme

Objective: To study and evaluate the incidence of pain and complications in patients with spinal trauma after minimally invasive treatment. Methods: The research period was selected from January 2018 to December 2020, and 40 patients with spinal trauma were selected. According to the random number table scheme, they were divided into the study group and the control group. The treatment scheme of the control group was traditional surgery, and the treatment scheme of the study group was minimally invasive surgery. The indicators of the two groups were compared and analyzed. Results: Compared with the two groups of surgery and postoperative recovery related indicators, the study group had more advantages (P<0.05); Compared two groups of postoperative NRS score, VAS score and the incidence of complications, the study group had more advantages(P<0.05). Conclusion: Minimally invasive treatment of spinal trauma has significant clinical effect, which can effectively relieve postoperative pain and reduce the incidence of various complications.

Download Full-text

Fuzheng Xiaoliu granules reduce the 2-year recurrence rate of early-stage hepatitis B virus-related hepatocellular carcinoma after comprehensive minimally invasive surgery: a study protocol for a prospective, multicenter, central randomized, double-blind, placebo-controlled clinical trial

10.21203/rs.3.rs-458191/v1 ◽

2021 ◽

Author(s):

Xinju Chen ◽

Suping Ma ◽

Xiaoqi Chen ◽

Yaokun Hao ◽

Qing Zhao ◽

...

Keyword(s):

Clinical Trial ◽

Hepatitis B Virus ◽

Hepatitis B ◽

Minimally Invasive ◽

Recurrence Rate ◽

Early Stage ◽

Minimally Invasive Treatment ◽

Control Group ◽

Invasive Treatment ◽

B Virus

Abstract Background: Hepatitis B virus (HBV) infection is one of the most common risk factors for hepatocellular carcinoma (HCC). With the continuous improvement of minimally invasive treatment techniques such as transarterial chemoembolization (TACE) and radiofrequency ablation (RFA), comprehensive minimally invasive treatment (TACE & RFA) has been widely used in the treatment of early-stage (Barcelona Clinic Liver Cancer (BCLC) stage 0 and A) HCC and has good safety and clinical efficacy. However, recurrence and metastasis after comprehensive minimally invasive treatment are still key factors affecting the survival rate of patients. In recent years, Chinese medicine has highlighted its unique advantages in the adjuvant treatment of liver cancer surgery and minimally invasive treatment. Thus, this study aimed to evaluate the efficacy and safety of Fuzheng Xiaoliu granules (FZXLG) for treating early-stage HBV-related HCC after comprehensive minimally invasive treatment and to explore whether FZXLG can delay the progression of HBV-related HCC. Methods: This is a prospective, multicenter, central randomized, double-blind, placebo-controlled clinical trial. A total of 312 patients with early HBV-related HCC who underwent comprehensive minimally invasive treatment within 2 months were randomized in a 1:1 ratio into two groups: the experimental group and the control group. The experimental group will receive basic FZXLG plus Western medicine treatment, and the control group will receive basic FZXLG simulator plus Western medicine treatment. Each group will be treated for 1 year and followed-up for 1 year. The primary outcome measure is the 2-year recurrence rate of patients with early-stage HBV-related HCC after minimally invasive treatment. The secondary outcomes include (1) measurable active lesions, (2) alpha-fetoprotein (AFP), (3) immunological indicators, such as comparison of CD3+, CD4+, CD8+ absolute values, CD4+/CD8+ before and after the test, (4) hepatitis B virus quantity, and (5) Karnofsky functional status score. Discussion: These results will provide research data on the efficacy and safety of FZXLG for the treatment of early-stage HBV-related HCC after comprehensive minimally invasive treatment. These findings will also be based on laboratory indicators and adverse events for safety assessment to determine whether FZXLG can reduce the 2-year recurrence rate of HCC after minimally invasive surgery, which will provide reliable evidence for the clinical treatment of HCC.Trial registration: Chinese Clinical Trial Registry, ChiCTR1900022999. Registered on 5 May 2019.

Download Full-text

Thromboembolic complications prevention in the obstetric practice

HEALTH OF WOMAN ◽

10.15574/hw.2017.117.19 ◽

2017 ◽

pp. 19-24

Author(s):

O.V. Grishchenko ◽

◽

V.V. Bobrytska ◽

Keyword(s):

Pulmonary Embolism ◽

Comparison Group ◽

Main Group ◽

Control Group ◽

Efficacy And Safety ◽

Thromboembolic Complications ◽

Moderate Risk ◽

Obstetric Practice ◽

Thrombotic Complications ◽

And Control

The objective: To evaluate the clinical efficacy and safety of Enoxaparin-Pharmex for the prevention of thrombotic complications (pulmonary embolism) in the postoperative period in patients with moderate risk of these complications. Patients and methods. The study included 50 women after a caesarean section had an average degree of risk of pulmonary embolism. Patients were divided into the main group (n=25) and control group (n=25) in accordance with the treatment: patients of the main group received postoperative Еnoxaparin- Pharmex, group comparisons enoxaparin sodium (brand foreign manufacturer’s). Patients in both groups received the drug at a dose of 20 mg for 5 days, 1 time per day subcutaneously. Results. The research data analysis showed identity results of hemostasiogram of patients in the main group and the comparison group, no side effects after treatment in both groups. Conclusion. The clinical studies suggest the drug Enoxaparin-Pharmex is effective, safe LMWH, which can be used to prevent troboembolic complications, including post-operative treatment in obstetric practice. Spectrum of Enoxaparin-Pharmex can be extended to the prevention and treatment of thromboembolic conditions of varying severity with appropriate doses of the drug. Key words: Enoxaparin-Pharmex, prevention of pulmonary embolism.

Download Full-text

Percutaneous Minimally Invasive Treatment for the Trigeminal Neuralgia: A Review

Journal of Anesthesia and Perioperative Medicine ◽

10.24015/japm.2015.0023 ◽

2015 ◽

Vol 2 (3) ◽

pp. 167-174

Author(s):

Xiang-Fei Guo ◽

Jun Ma

Keyword(s):

Trigeminal Neuralgia ◽

Minimally Invasive ◽

Minimally Invasive Treatment ◽

Invasive Treatment

Download Full-text

EAU, AUA and NICE Guidelines on Surgical and Minimally Invasive Treatment of Benign Prostate Hyperplasia: A Critical Appraisal of the Guidelines Using the AGREE-II Tool

Urologia Internationalis ◽

10.1159/000517675 ◽

2021 ◽

pp. 1-10

Author(s):

Dmitry Enikeev ◽

Vincent Misrai ◽

Enrique Rijo ◽

Roman Sukhanov ◽

Denis Chinenov ◽

...

Keyword(s):

Minimally Invasive ◽

Treatment Options ◽

Stakeholder Involvement ◽

Minimally Invasive Treatment ◽

Invasive Treatment ◽

Agree Ii ◽

Prostate Hyperplasia ◽

Assessment Score ◽

Nice Guideline ◽

Agree Ii Tool

Objective: To critically appraise the methodological rigour of the clinical practice guidelines (CPGs) vis-à-vis BPH surgery as used by specialist research associations in the US, Europe and UK, and to compare whether the guidelines cover all or only some of the available treatments. Methods: The current guidelines issued by the EUA, AUA and NICE associations have been analyzed by 4 appraisers using the AGREE-II instrument. We also compared the recommendations given in the guidelines for surgical and minimally invasive treatment to find out which of these CPGs include most of the available treatment options. Results: According to the AGREE II tool, the median scores of domains were: domain 1 scope and purpose 66.7%, domain 2 stakeholder involvement 50.0%, domain 3 rigor of development 65.1%, domain 4 clarity of presentation 80.6%, domain 5 applicability 33.3%, domain 6 editorial independence 72.9%. The overall assessment according to AGREE II is 83.3%. The NICE guideline scored highest on 5 out of 6 domains and the highest overall assessment score (91.6%). The EAU guideline scored lowest on 4 out of 6 domains and has the lowest overall assessment score (79.1%). Conclusions: The analyzed CPGs comprehensively highlight the minimally invasive and surgical treatment options for BPH. According to the AGREE II tool, the domains for clarity of presentation and editorial independence received the highest scores. The stakeholder involvement and applicability domains were ranked as the lowest. Improving the CPG in these domains may help to improve the clinical utility and applicability of CPGs.

Download Full-text